Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Karyopharm Therapeutics (NASDAQ: KPTI) with a Overweight rating.The analyst comments: "We are ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE